On December 3, 2018, Healthcare Value Capital, LLC sent a letter to the Board of Directors of Novelion Therapeutics Inc. Healthcare Value stated that it expects the Company faithfully and thoroughly explore all strategic alternatives and not simply choose the most expedient solution for the debt-holders at the expense of the equity-holders. In addition, Healthcare Value stated that it would welcome the opportunity to meet with the management of the Company to discuss Healthcare Value’s thoughts on an immediate program to decisively and permanently normalize costs as well as the relative merits, timing, and terms for the strategic alternatives available to the Company.